Baldwin Brothers LLC Viking Therapeutics, Inc. Transaction History
Baldwin Brothers LLC
- $1.43 Billion
- Q3 2024
A detailed history of Baldwin Brothers LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Baldwin Brothers LLC holds 150 shares of VKTX stock, worth $6,402. This represents 0.0% of its overall portfolio holdings.
Number of Shares
150Holding current value
$6,402% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding VKTX
# of Institutions
473Shares Held
65.6MCall Options Held
5.72MPut Options Held
3.39M-
Vanguard Group Inc Valley Forge, PA10.2MShares$434 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$257 Million0.01% of portfolio
-
State Street Corp Boston, MA4.67MShares$199 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.12MShares$90.3 Million0.01% of portfolio
-
Morgan Stanley New York, NY1.87MShares$80 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $3.27B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...